Rocket


Overview
Financials
News + Filings

 
 

Inhibikase Therapeutics, Inc. Add to portfolio


Recent News + Filings   (All items)

Financial Summary   (All financials)
In millions, except per share itemsDec-31-19Dec-31-18
Revenues1.14.0
            Revenue growth-72.2% 
Cost of goods sold2.63.6
Gross profit-1.40.4
            Gross margin-127.4%9.7%
Selling, general and administrative4.32.5
EBIT-5.7-2.1
            EBIT margin-507.5%-52.5%
Pre-tax income-5.7-2.2
Income taxes0.00.0
            Tax rate0.0%0.0%
Net income-5.7-2.2
            Net margin-509.7%-53.3%
 
 
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy